FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

A common anti-nausea drug used during chemotherapy may do more than ease discomfort, it could help women with aggressive ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

Cancer Antibody Drug Conjugates Treatment Market USD 50 Billion Opportunity Says Kuick Research. Delhi, July 11, 2025 (GLOBE ...

Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, discusses how Emrelis fits into the current antibody-drug conjugate landscape and what distinguishes its approach in biomarker-driven ...

Celcuity receives US patent for its lead drug candidate, gedatolisib; getting exclusivity up to 2042: Minneapolis Thursday, July 17, 2025, 16:00 Hrs [IST] Minneapolis-headquartere ...

The global HER2+ gastric cancer market is experiencing significant growth, driven by the rising incidence of gastric cancer and increased healthcare investments. HER2-positive gastric cancer, ...

A new drug targets RAS-PI3Kα pathways without harmful side effects. It was developed using high-performance computing and AI.

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) (OTCPK:RHHVF) said that the European Commission has approved its oral cancer drug, Itovebi (inavolisib), to be used alongside palbociclib and fulvestrant for breast ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and HER2 ...